EDX Medical Group (EDX ) has announced a cancer biomarker programme aimed at improving access to affordable and reliable tests for a range of cancers in the UK and Europe.
The programme is the result of a collaboration between EDX and Tianjin Bioscience Diagnostic Technology (Bioscience), an international manufacturer of diagnostics products. EDX was selected by Bioscience as its lead partner to validate and commercialise a suite of cancer biomarkers in Europe.
The programme will encompass the validation and clinical deployment of Bioscience's digital chemiluminescence immunoassay technology for an initial 10 cancer biomarkers, including key glycoprotein carbohydrate antigens CA-15-3, CA19-9, CA-125, and CA-72-4.
These biomarkers are recognised as important tools to improve the clinical management of a range of cancers, and will be deployed individually and in combination using Bioscience's automated analysers.
Per the agreement, Bioscience has installed two automated digital chemiluminescence immunoassay instruments at EDX's laboratory in Cambridge, UK, with an initial capability of up to 250,000 tests/year.
As part of the programme, EDX will conduct validation studies and submit data to UK and EU authorities for regulatory approval.
Dr Mike Hudson, CEO of EDX Medical, commented: "We are delighted to announce this collaboration with Bioscience, which will accelerate access to these highly reliable, affordable laboratory tests for doctors, patients and cancer survivors in the UK and Europe. The automation and combination of tests means improved flexibility, enhanced data and rapid delivery of test results".
View from Vox
Today's news marks an important milestone for EDX. The partnership with Bioscience will unlock access to large-scale automated analysis, in turn accelerating the development of reliable and cost-effective cancer tests for doctors and patients in the UK and Europe.
The partnership will directly support EDX's strategy to offer a complete suite of cancer tests in the UK, enabled by definitive functional genomics from its Cambridge lab. This is all the more relevant post-pandemic as the world grapples with long backlogs of cancer patients needing fast and effective diagnostic products.
We recommend investors interested in the sector EDX as it progresses toward validation and commercialisation of Bioscience's suite of cancer biomarkers. Beyond this project, EDX and Bioscience plan to co-develop further oncology tests.